STOCK TITAN
  1. Home
  2. Sec-filings
  3. EKSO
  4. [Form 4] EKSO BIONICS HOLDINGS, INC. Insider Trading Activity

EKSO Form 4: CFO receives 19,500 fully vested RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ekso Bionics (EKSO) reported an insider equity award for its Chief Financial Officer. On 11/05/2025, the officer acquired 19,500 restricted stock units (RSUs) at $0 under the Amended and Restated 2014 Equity Incentive Plan. The filing states each RSU equals one share and the award was fully vested at grant.

Following the transaction, the officer beneficially owned 37,297 shares directly and 2,876 shares indirectly via a 401(k). The company previously implemented a 1-for-15 reverse stock split on June 2, 2025, and amounts reflect that adjustment.

Positive

  • None.

Negative

  • None.
Insider Wong Jerome
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Common Stock 19,500 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 37,297 shares (Direct); Common Stock — 2,876 shares (Indirect, By 401(k))
Footnotes (1)
  1. Represents restricted stock units ("RSUs"). Each RSU represents the economic equivalent of one share of EKSO common stock and shall be settled in shares of EKSO common stock upon vesting. The RSU grant was approved by the Board of Directors in a meeting held on November 5, 2025, under the Company's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). Each RSU Award was fully vested at grant. On June 2, 2025, the Issuer effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wong Jerome
(Last) (First) (Middle)
101 GLACIER POINT
SUITE A
(Street)
SAN RAFAEL CA 94901
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
EKSO BIONICS HOLDINGS, INC. [ EKSO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/05/2025 A 19,500(1)(2) A $0 37,297(3) D
Common Stock 2,876(3) I By 401(k)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents restricted stock units ("RSUs"). Each RSU represents the economic equivalent of one share of EKSO common stock and shall be settled in shares of EKSO common stock upon vesting.
2. The RSU grant was approved by the Board of Directors in a meeting held on November 5, 2025, under the Company's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). Each RSU Award was fully vested at grant.
3. On June 2, 2025, the Issuer effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
/s/ Jerome Wong 11/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did EKSO disclose on Form 4?

The CFO acquired 19,500 RSUs at $0 on 11/05/2025.

What does each RSU represent for EKSO?

Each RSU represents the economic equivalent of one share of EKSO common stock and settles in shares upon vesting.

Were the RSUs vested at grant for EKSO's CFO?

Yes. The filing states the RSU award was fully vested at grant.

What is the EKSO officer’s beneficial ownership after the transaction?

Beneficial ownership is 37,297 shares directly and 2,876 shares indirectly via a 401(k).

Under which plan were the EKSO RSUs granted?

The award was granted under the Amended and Restated 2014 Equity Incentive Plan.

How does the reverse stock split affect reported amounts for EKSO?

A 1-for-15 reverse stock split on June 2, 2025 adjusted the reported share amounts.